Coeptis Therapeutics 

$10.87
0
+$0+0% Monday 00:08

Statistics

Day High
10.87
Day Low
9.51
52W High
-
52W Low
-
Volume
48
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q4 2024
Q3 2025
Q4 2025
Next
-0.8
-0.47
-0.13
0.2
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COEP.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes in the development of innovative therapies, similar to Coeptis Therapeutics' focus on novel treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm that develops therapeutic solutions in various disease areas, competing with Coeptis Therapeutics in the biopharmaceutical space.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines, making it a competitor in the pharmaceutical and biotech industry.
Merck
MRK
Mkt Cap214.76B
Merck operates in the pharmaceutical sector, focusing on innovative drug development and directly competing with companies like Coeptis Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company with a wide range of products and research areas, overlapping with Coeptis Therapeutics' interests.
Novartis
NVS
Mkt Cap237.61B
Novartis is a healthcare company that engages in the research, development, and marketing of healthcare products, competing in the same space as Coeptis Therapeutics.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a research-based biopharmaceutical company, its diverse range of pharmaceutical products places it in competition with Coeptis Therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, making it a competitor in the healthcare sector.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a comprehensive healthcare firm that competes across various segments, including pharmaceuticals, which overlaps with Coeptis Therapeutics' operations.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a leading biotechnology company that develops and commercializes medicines for serious medical conditions, competing in the biopharmaceutical field.

About

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Show more...
CEO
ISIN
US19207A2078

Listings

0 Comments

Share your thoughts

FAQ

What is Coeptis Therapeutics stock price today?
The current price of COEP.BOATS is $10.87 USD — it has increased by +0% in the past 24 hours. Watch Coeptis Therapeutics stock price performance more closely on the chart.
What is Coeptis Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Coeptis Therapeutics stocks are traded under the ticker COEP.BOATS.
When is the next Coeptis Therapeutics earnings date?
Coeptis Therapeutics is going to release the next earnings report on June 03, 2026.
When did Coeptis Therapeutics complete a stock split?
Coeptis Therapeutics has not had any recent stock splits.